Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
Neoadjuvant therapy with pembrolizumab plus chemotherapy provides greater anti-tumour activity than placebo plus chemotherapy in patients with early stage triple negative breast cancer
Adding veliparib to carboplatin and paclitaxel doubled the 3-year progression-free survival rate over carboplatin and paclitaxel
Exploratory analysis of FLAURA data demonstrates that longitudinal ctDNA monitoring can provide early detection of disease progression and/or resistance in advanced NSCLC
The results from LIBRETTO-001 trial
TRIUMPH and MOUNTAINEER demonstrate promising clinical benefit for dual HER2 blockade in patients with HER2-amplified metastatic CRC; however, HERACLES-B did not meet the primary endpoint
A subset of patients with MSI-H tumours demonstrated superior benefit from pembrolizumab, both in combination with chemotherapy or as monotherapy
Differences in patient outcome were observed in four molecular subgroups after adjuvant chemotherapy plus radiotherapy or radiotherapy
Gut microbial metabolites may alter the activity of immune blockade agents
The veliparib consisting regimen improved progression-free survival in the overall patient population and among women with BRCA mutation or HRD as compared to chemotherapy
Niraparib administered after platinum-based chemotherapy improved progression-free survival in patients with ovarian cancer regardless of BRCA status
Progression-free survival was significantly increased with olaparib plus bevacizumab as maintenance therapy overall and across prespecified subgroups
Complementary medicines are mostly used by younger patients with better performance status and fewer sites of metastasis
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.
